These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28074487)

  • 1. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases.
    Winter RW; Collins E; Cao B; Carrellas M; Crowell AM; Korzenik JR
    Aliment Pharmacol Ther; 2017 Mar; 45(5):653-659. PubMed ID: 28074487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases.
    Zator ZA; Cantu SM; Konijeti GG; Nguyen DD; Sauk J; Yajnik V; Ananthakrishnan AN
    JPEN J Parenter Enteral Nutr; 2014; 38(3):385-91. PubMed ID: 24088707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relevance of Vitamin D and Antinuclear Antibodies in Patients with Inflammatory Bowel Disease Under Anti-TNF Treatment: A Prospective Study.
    Santos-Antunes J; Nunes AC; Lopes S; Macedo G
    Inflamm Bowel Dis; 2016 May; 22(5):1101-6. PubMed ID: 26818421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
    Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
    J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
    Colman RJ; Rubin DT
    J Crohns Colitis; 2015 Apr; 9(4):312-7. PubMed ID: 25616487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Vitamin D on Response to Anti-tumor Necrosis Factor-α Therapy in Children With Inflammatory Bowel Disease.
    Hizarcioglu-Gulsen H; Kaplan JL; Moran CJ; Israel EJ; Lee H; Winter H
    J Pediatr Gastroenterol Nutr; 2021 May; 72(5):e125-e131. PubMed ID: 33847289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up.
    Lehtola E; Haapamäki J; Färkkilä MA
    Scand J Gastroenterol; 2016 Dec; 51(12):1476-1481. PubMed ID: 27686143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
    Miler M; Nikolac Gabaj N; Ćelap I; Grazio S; Tomašić V; Bišćanin A; Mitrović J; Đerek L; Morović-Vergles J; Vrkić N; Štefanović M
    Rheumatol Int; 2021 Dec; 41(12):2195-2203. PubMed ID: 34623480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.
    Kiely CJ; Subramaniam K; Platten J; Pavli P
    Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Nugent Z; Singh H; Bernstein CN
    Inflamm Bowel Dis; 2017 Mar; 23(3):409-420. PubMed ID: 28221250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
    Porcari S; Viola A; Orlando A; Privitera AC; Ferracane C; Cappello M; Vitello A; Siringo S; Inserra G; Magnano A; Mocciaro F; Di Mitri R; Belluardo N; Fidanza O; Garufi S; Magrì G; Bertolami C; Carroccio A; Macaluso FS; Renna S; Ventimiglia M; Alibrandi A; Cottone M; Fries W;
    Drugs Aging; 2020 May; 37(5):383-392. PubMed ID: 32016824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
    Mechie NC; Mavropoulou E; Ellenrieder V; Kunsch S; Cameron S; Amanzada A
    Digestion; 2020; 101(6):761-770. PubMed ID: 31536991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors.
    Grosen A; Bungum M; Christensen LA; Cordelli E; Larsen OH; Leter G; Julsgaard M; Vestergaard T; Villani P; Hvas CL; Kelsen J
    J Crohns Colitis; 2019 Apr; 13(5):564-571. PubMed ID: 30500868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy.
    Pratt PK; David N; Weber HC; Little FF; Kourkoumpetis T; Patts GJ; Weinberg J; Farraye FA
    Inflamm Bowel Dis; 2018 Jan; 24(2):380-386. PubMed ID: 29361083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
    Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.